← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $252B	1,113	+68	+7%	$48.6B
2	2 Danaher DHR $161B	1,105	+60	+6%	$41.4B
3	3 Novartis NVS $287B	905	+28	+3%	$18.2B
4	4 Regeneron Pharmaceuticals REGN $82.5B	576	+21	+4%	$26.3B
5	5 Agilent Technologies A $49.5B	553	-4	-0.7%	$12.6B
6	6 Illumina ILMN $40B	529	-24	-4%	$17.5B
7	7 Revvity RVTY $16.7B	326	+2	+0.6%	$5.36B
8	8 Ionis Pharmaceuticals IONS $7.34B	309	+26	+9%	$5.2B
9	9 Charles River Laboratories CRL $14.3B	297	+13	+5%	$3.52B
10	10 Myriad Genetics MYGN $402M	223	-1	-0.4%	$1.35B
11	11 Bruker BRKR $8.37B	212	+2	+1%	$2.32B
12	12 Alnylam Pharmaceuticals ALNY $30.9B	211	-49	-19%	$2.99B
13	13 DELISTED CATALENT, INC. CTLT	206	+4	+2%	$3.45B
14	14 DELISTED bluebird bio BLUE	199	-2	-1%	$2.88B
15	15 Azenta AZTA $1.61B	181	+23	+15%	$1.1B
16	16 Sarepta Therapeutics SRPT $1.84B	178	-10	-5%	$1.08B
17	17 Ultragenyx Pharmaceutical RARE $1.49B	175	+1	+0.6%	$2.93B
18	18 Precigen PGEN $2.64B	171	+2	+1%	$2.42B
19	ISEE 19 DELISTED IVERIC bio, Inc. Common Stock ISEE	137	-55	-29%	$113M
20	20 DELISTED SANGAMO THERAPEUTICS INC SGMO	126	+1	+0.8%	$127M
21	21 PTC Therapeutics PTCT $5.16B	123	+7	+6%	$313M
22	22 Pacific Biosciences PACB $603M	115	-13	-10%	$240M
23	NSTG 23 DELISTED NanoString Technologies, Inc. NSTG	111	+10	+10%	$440M
24	SIOX 24 DELISTED Sio Gene Therapies Inc. Common Stock SIOX	101	+6	+6%	$1.25B
25	25 Lineage Cell Therapeutics LCTX $237M	92	+12	+15%	$146M